Edward A Medina, M.D.

Research

Dr. Medina received his undergraduate degree in Molecular and Cell Biology from the University of California, Berkeley. He graduated from the Physician-Scientist (M.D./Ph.D.) Training Program at the University of California, Davis, and then completed a residency in Anatomic and Clinical Pathology followed by a fellowship in Hematopathology at UT Health San Antonio. He is board-certified in clinical pathology and hematopathology. He is currently an Assistant Professor of Pathology in the School of Medicine at UT Health San Antonio. He is a clinically active physician with a specialty in hematopathology. He directs a research program that is focused on mechanistically understanding how obesity/insulin resistance/diabetes influences the development/progression of multiple myeloma (MM), as well as their role in chemoresistance, in order to identify novel targets for clinical translation. His laboratory has generated compelling preliminary evidence which suggests that elevated levels of oxidized low-density lipoprotein (OxLDL) contribute to resistance against proteasome inhibitors (PI) in MM patients with hypercholesterolemia/dyslipidemia. They are conducting a series of in vitro and in vivo studies that aim to reveal key pathways involved in mediating the protective effect of OxLDL against PI-induced MM cell killing, and evaluate the potential of suppressing elevated OxLDL levels associated with hypercholesterolemia/dyslipidemia to enhance MM responsiveness to therapeutic PIs.

Relevant Diseases

Obesity, diabetes, multiple myeloma

• Professional Background

  Education

  • 2011 - Clinical Fellowship - Hematopathology - University of Texas Health Science Center
  • 2009 - Residency - Pathology - University of Texas Health Science Center
  • 2005 - MD - Doctor of Medicine - University of California
  • 2003 - PhD - Immunology - University of California
  • 1993 - BA - Molecular and Cell Biology - University of California

  Appointments

  • 7/2011 - Assistant Professor - University of Texas Health Science Center, Pathology, San Antonio

• Instruction & Training

  • 4/2015 - Present, Cancer Biology Core II, The University of Texas Health Science Center
  • 10/2014 - Present, Plasma Cell Neoplasms, University of Texas Health Science Center San Antonio
  • 9/2009 - Present, Hematopathology Module, General Pathology (PATH 21205) for 2nd Year Medical Students, University of Texas Health Science Center San Antonio

• Research & Grants

  Dr. Medina received his undergraduate degree in Molecular and Cell Biology from the University of California, Berkeley. He graduated from the Physician-Scientist (M.D/Ph.D) Training Program at the University of California, Davis, and then completed a residency in Anatomic and Clinical Pathology followed by a fellowship in Hematopathology at UT Health San Antonio. He is board-certified in clinical pathology and hematopathology. He is currently an Assistant Professor of Pathology in the School of Medicine at UT Health San Antonio. 

  Research profile

  Grants

  Private

  Funding Agency Voelcker Fund Title Pro-Myeloma Influence of Adipocyte-Derived Fatty Acids and Tumor Cell Lipogenesis Status Active Period 7/2014 - 6/2017 Role Principal Investigator Grant Detail  

• Publications

  Abstract

  Cortez V, Oyajobi B, Medina EA. PKA/AMPK signaling in relation to adiponectin's antiproliferative effect on multiple myeloma cells; 2015 Nov. (CTRC Symposium). Medina EA, Polusani SR, Oberheu K, Oyajobi BO. PKA/AMPK signaling is a mediator of the anti-proliferative effect of adiponectin on multiple myeloma cells; 2014 Apr. (5th Annual Frontiers of Translational Science Research Day, UTHSCSA).

  Journal Article

  Medina EA, Fuehrer NE, Miller FR, Kinney MC, Higgins RA. Dysplastic Follicular Dendritic Cells in Hyaline-Vascular Castleman Disease: A Rare Occurrence Creating Diagnostic Difficulty Pathol Int 2016 Sep;66(9):535-539. Habib SL, Al-Obaidi, Nowacki M, Drewa T, Medina E, Zhao Z and Liang S. Is mTOR inhibitor good enough for treatment all tumors in TSC Patients? (Corresponding Author) J Cancer 2016 Jul;7:1621-1631. Medina EA, Oberheu K, Polusani SR, Ortega V, Velagaleti GV, Oyajobi BO. PKA/AMPK signaling in relation to adiponectin's antiproliferative effect on multiple myeloma cells Leukemia 2014 Oct;28(10):2080-2089. Medina EA, Morris IR, Berton MT. Phosphatidylinositol 3-kinase activation attenuates the TLR2-mediated macrophage proinflammatory cytokine response to Francisella tularensis live vaccine strain J Immunol 2010 Dec;185(12):7562-7572. Cadena Zuluaga JA, Thompson GR, Ho TT, Medina EA, Hughes DW, Patterson TF. Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor alpha blocker adalimumab in cryptococcal pneumonia Diagn Microbiol Infec Dis 2009 Jul;64(3):327-330.

• Clinical

  Board Certifications

  • American Board of Pathology/Clinical
  • American Board of Pathology/Hematology